Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering

Adeno-associated virus (AAV) gene therapy has shown immense promise in treating various genetic disorders. Reducing AAV production costs will enable its use on a larger scale, and make gene therapy more accessible to a broader population. Enhancements in AAV productivity and genome packaging efficiency, specifically the full-to-total capsid ratio (F/T ratio) can result in more effective therapies, at reduced cost. In this webinar, we will present plasmid and cell engineering approaches to enhance these aspects in HEK293 cell line platforms.

Firstly, we will discuss novel design engineering in the pHelper and pRepCap plasmids to support increased AAV titers and an improved F/T ratio in the upstream crude harvest using a triple-plasmid transfection process. The performance of this platform has been independently measured at both Lonza and Bristol Myers Squibb R&D labs, demonstrating significant improvements across various AAV serotypes and client-specific genes of interest (GOIs).

The development of our helper virus-free AAV Producer Cell Line (PCL) platform technology will also be described. Leveraging proprietary high-producer HEK293 cells, selected PCL clones have demonstrated superior performance with higher AAV titers (>1E12 vg/mL) and comparable-high AAV genome packaging (>30% full capsids) at harvest. This technology enables high-quality commercial AAV manufacturing with significantly reduced costs and process complexity.

These AAV Transient and PCL platforms represent a leap into next-generation technologies that are set to drive gene therapy commercialization.

• F/T ratio is an important measure that can help drive COGS reduction for AAV-based gene therapy drugs along with titer increments
• Various plasmid and cell engineering approaches can help achieve significant process improvements
• Lonza platform technologies are available to Pharma and Biotechs to license to own labs for evaluation

Lisa Prendergast

Subject Matter Expert, Expression systems at Lonza

Dr. Lisa Prendergast is a Molecular Technologies Expert within Licensing at Lonza. Her role is to provide global support with in-depth scientific and technical direction to those working with various expression system platforms through ‘Lonza in Your Lab®’ programs. She is an expert in Cell and Molecular Biology including vector-based gene expression systems and sequence-based technologies supporting the development of complex biologicals.

Dr. Prendergast has extensive discovery research experience from her postdoctoral work in Ireland, France, and the UK. As a Senior Research Associate and Lead Biologist for Cancer Research UK, she worked within target validation for early-stage oncology drug discovery programs. She holds a PhD in Biochemistry from the National University of Ireland, Galway.

Watch now

SPEAKERS

Lisa Prendergast

Subject Matter Expert, Expression systems at Lonza

You might also like

Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Sunil Acharya

1 August

in 30

Days

Register

Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency

K Doucette, F Voss, R Vancini

25 July

in 23

Days

Register

Development of a non-viral gene delivery platform for CAR-T manufacturing

S Feldman, J Brady, D Nguyen

24 July

in 22

Days

Register

Supporting efficacy and scaling with a next-generation T cell AOF formulation medium

Alan Gutowski, Joanna Kern

23 July

in 21

Days

Register

Navigating cold chain complexity with innovative solutions

Susan Li

17 July

in 15

Days

Register